FIELD: medicine.
SUBSTANCE: group of inventions relates to a method of treating or slowing the progression of non-squamous non-small cell lung cancer (NSCLC) in an individual, comprising administering to an individual an effective amount of an antagonist binding to a component of the PD-1 signaling pathway, taxane and a platinum-based chemotherapeutic agent, wherein the taxane is nab-paclitaxel or paclitaxel. Group of inventions also relates to a method of enhancing immune function in an individual with non-squamous NSCLC, comprising administering an antagonist which binds to a component of a PD-1 signaling pathway, taxane and a platinum-based chemotherapeutic agent; combinations for treating or slowing the progression of non-flat-cell NSCLC in an individual; kit for treating or delaying the progression of non-squamous NSCLC in an individual.
EFFECT: group of inventions provides a strong antitumour effect, including a high frequency of "complete remission", id est no detectable tumor mass.
95 cl, 2 ex, 6 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| HUMANIZED ANTIBODIES AND ANTIBODIES WITH MATURE AFFINITY AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2748943C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| TARGETED TGF BETA INHIBITION | 2015 |
|
RU2752424C2 |
